Search
Disc Medicine Inc
IRONAdd to Watchlist
74.950USD
+1.810+2.47%
Close 07/01, 16:00（ET）Quotes delayed by 15 min
2.84BMarket Cap
LossP/E TTM
More Details of Disc Medicine Inc Company
Disc Medicine, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases. The Company's pipeline includes bitopertin for the treatment of erythropoietic porphyrias (Eps), including erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF), and anemia of chronic kidney disease (CKD), and DISC-3405 (formerly MWTX-003) for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, its preclinical programs also include DISC-0998, for the treatment of anemia associated with inflammatory diseases. Bitopertin is the lead product candidate in the Company's heme biosynthesis modulation portfolio. It is developing DISC-3405, a monoclonal antibody against Transmembrane Serine Protease 6 that it licensed from Mabwell Therapeutics, Inc.
Disc Medicine Inc Info
Ticker SymbolIRON
Company nameDisc Medicine Inc
IPO dateAug 12, 2020
CEOQuisel (John D)
Number of employees84
Security typeOrdinary Share
Fiscal year-endAug 12
Address321 Arsenal Street, Suite 101
CityWATERTOWN
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code02472
Phone16176749274
Websitehttps://www.discmedicine.com/
Ticker SymbolIRON
IPO dateAug 12, 2020
CEOQuisel (John D)
Company Executives of Disc Medicine Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Rahul Khara, Pharm.D.
Dr. Rahul Khara, Pharm.D.
Chief Legal Officer
Chief Legal Officer
51.02K
--
Ms. Pamela Stephenson
Ms. Pamela Stephenson
Chief Commercial Officer
Chief Commercial Officer
18.66K
+6.25%
Dr. Georges Gemayel, Ph.D.
Dr. Georges Gemayel, Ph.D.
Director
Director
--
--
Dr. John D. Quisel, J.D., Ph.D.
Dr. John D. Quisel, J.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Dr. Donald W. (Don) Nicholson, Ph.D.
Dr. Donald W. (Don) Nicholson, Ph.D.
Executive Chairman of the Board
Executive Chairman of the Board
--
--
Mr. Kevin J. Bitterman, Ph.D.
Mr. Kevin J. Bitterman, Ph.D.
Independent Director
Independent Director
--
--
Mr. Mark Chin
Mr. Mark Chin
Independent Director
Independent Director
--
--
Dr. Liam T. Ratcliffe, M.D., Ph.D.
Dr. Liam T. Ratcliffe, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. William White, J.D.
Mr. William White, J.D.
Independent Director
Independent Director
--
--
Dr. William Savage, M.D., Ph.D.
Dr. William Savage, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Rahul Khara, Pharm.D.
Dr. Rahul Khara, Pharm.D.
Chief Legal Officer
Chief Legal Officer
51.02K
--
Ms. Pamela Stephenson
Ms. Pamela Stephenson
Chief Commercial Officer
Chief Commercial Officer
18.66K
+6.25%
Dr. Georges Gemayel, Ph.D.
Dr. Georges Gemayel, Ph.D.
Director
Director
--
--
Dr. John D. Quisel, J.D., Ph.D.
Dr. John D. Quisel, J.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Dr. Donald W. (Don) Nicholson, Ph.D.
Dr. Donald W. (Don) Nicholson, Ph.D.
Executive Chairman of the Board
Executive Chairman of the Board
--
--
Mr. Kevin J. Bitterman, Ph.D.
Mr. Kevin J. Bitterman, Ph.D.
Independent Director
Independent Director
--
--
FAQs
Who are the top five shareholders of Disc Medicine Inc?
The top five shareholders of Disc Medicine Inc are: Dr. Rahul Khara, Pharm.D.
How many institutions hold shares of Disc Medicine Inc (IRON)?
As of 2026Q1, 399 institutions hold shares of Disc Medicine Inc, with a combined market value of approximately 42.26M, accounting for 110.63% of the total shares. Compared to 2025Q4, institutional shareholding has increased by 1071670.00.